ACADIA PHARMACEUTICALS INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.42 USD | -10.01% |
|
-9.07% | -50.40% |
| 06:04pm | Stifel Adjusts Price Target on ACADIA Pharmaceuticals to $21 From $26, Keeps Hold Rating | MT |
| May. 08 | Transcript : ACADIA Pharmaceuticals Inc., Q1 2024 Earnings Call, May 08, 2024 |
Presenter SpeechRajesh Narendran (Attendees)Okay. Good morning. I assume we're okay to start. ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
17.13
USD
Average target price
28.75
USD
Spread / Average Target
+67.82%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -50.40% | 2.83B | |
| +23.80% | 46.71B | |
| +48.83% | 41.8B | |
| -1.01% | 41.52B | |
| -5.86% | 29.55B | |
| +10.96% | 25.78B | |
| -20.74% | 19.26B | |
| +2.71% | 12.14B | |
| -2.86% | 12.08B | |
| +30.14% | 11.98B |
- Stock Market
- Equities
- ACAD Stock
- News ACADIA Pharmaceuticals Inc.
- Transcript : ACADIA Pharmaceuticals Inc. - Special Call